UK NICE gives draft guidance recommending use of Afinitor (everolimus) in advanced renal cell carcinoma- Novartis
The UK's National Institute for Health and Care Excellence has published new draft guidelines recommending Afinitor (everolimus), from Novartis, as an option for treating advanced renal cell carcinoma that has progressed during or after treatment with VEGF targeted therapy.
NICE originally gave advice rejecting the drug in April 2011. Afinitor was later made available via the Cancer Drug Fund. During a reappraisal of Afinitor as part of a programme NICE is carrying out to reassess the cost-effectiveness of medicines provided via the CDF, Novartis has offered a discount on the drug's cost of £32,076 per patient.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.